| Table S1. Demographic and Clinical Characteristics of Cohorts of Patients on SSRIs and statins
| SSRI
| SA or FL
| PA
| PA, SA, or FL
| PA
| SA
| FL
| Statin
| AT, SI, RO, or LO
| AT, SI, RO, or LO
| PR
| PR
| AT
| SI
| RO
| LO
| PR
| AT
| SI
| RO
| PR
| AT
| SI
| RO
| LO
| N
| 324
| 115
| 38
| 8
| 49
| 53
| 7
| 10
| 12
| 76
| 61
| 14
| 18
| 49
| 45
| 13
| 12
| Demographics
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Age
(mean ± SD)
| 66.9
± 13.6
| 67.9
± 13.5
| 61.2
± 16.4
| 63.1
± 10.1
| 68.0
± 13.7
| 69.8
± 14.6 †
| 60.9
± 17.2
| 68.0
± 8.9
| 57.8
± 15.9
| 71.4
± 12.7 †
| 69.1
± 13.9 †
| 56.9
± 10.1
| 62.7
± 18.6
| 68.1
± 12.2
| 66.5
± 14.1
| 65.6
± 7.0
| 60.9
± 12.4
| Gender (% Female)
| 57 †
| 56†
| 55
| 88
| 55
| 55
| 57
| 60
| 67
| 57
| 51 †
| 57
| 33 †
| 63
| 64
| 62
| 75
| Race (% of group)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| | 65
| 62
| 71
| 63
| 67
| 60
| 71
| 40
| 83
| 63
| 64
| 71
| 67
| 65
| 62
| 69
| 25
| | 3
| 3
| 5
| 0
| 4
| 4
| 0
| 0
| 0
| 8
| 3
| 0
| 11
| 2
| 0
| 0
| 8
| | 7
| 0
| 0
| 8
| 2
| 4
| 14
| 0
| 0
| 13
| 5
| 7
| 0
| 4
| 9
| 8
| 17
| | 25
| 36
| 24
| 30
| 27
| 32
| 14
| 60
| 17
| 16
| 28
| 21
| 22
| 29
| 29
| 23
| 50
| Glucose (mg/dl ± 95% CI)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Baseline (base)
| 126.5
± 4.2 †
| 123.3
± 6.8
| 113.5
± 8.7
| 112.6
± 11.1
| 128.5
± 12.2
| 126.2
± 8.5
| 103.3
± 13.1
| 117.6
± 21.3
| 118.5
± 20.7
| 121.3
± 6.9
| 125.5
± 9.8
| 117.7
± 14.8
| 110.5
± 11.0
| 114.8
± 6.3
| 122.7
± 9.7
| 116.1
± 10.9
| 128.4
± 19.0
| | 7.0
± 0.2
| 6.8
± 0.4
| 6.3
± 0.5
| 6.2
± 0.6
| 7.1
± 0.7
| 7.0
± 0.5
| 5.7
± 0.7
| 6.5
± 1.2
| 6.6
± 1.1
| 6.7
± 0.4
| 7.0
± 0.5
| 6.5
± 0.8
| 6.1
± 0.6
| 6.4
± 0.3
| 6.8
± 0.5
| 6.4
± 0.6
| 7.1
± 1.1
| After treatment(s) (post)
| 128.2
± 3.4
| 127.6
± 6.6
| 123.0
± 8.6
| 135.2
± 13.8
| 136.9
± 12.8
| 125.5
± 6.8
| 106.4
± 6.5 †
| 123.3
± 16.9
| 125.9
± 18.6
| 122.1
± 6.4
| 119.0
± 5.9
| 129.9
± 10.9
| 115.6
± 10.8 †
| 121.4
± 5.9
| 129.7
± 9.8
| 117.1
± 12.0
| 130.1
± 16.9
| | 7.1
± 0.2
| 7.1
± 0.4
| 6.8
± 0.5
| 7.5
± 0.8
| 7.6
± 0.7
| 7.0
± 0.4
| 5.9
± 0.4
| 6.8
± 0.9
| 7.0
± 1.0
| 6.8
± 0.4
| 6.6
± 0.3
| 7.2
± 0.6
| 6.4
± 0.6
| 6.7
± 0.3
| 7.1
± 0.5
| 6.5
± 0.7
| 7.2
± 0.9
| Change (base to post)
| 1.7
± 3.0 †
| 4.2
± 5.5
| 9.5
± 6.4
| 22.6
± 16.5
| 8.4
± 10.1
| -0.7
± 6.8 †
| 3.1
± 9.3
| 5.7
± 11.1
| 7.4
± 9.3
| 0.8
± 5.6 †
| -6.5
± 7.1 †
| 12.2
± 11.3
| 5.1
± 8.8
| 6.6
± 4.8
| 7.0
± 7.0
| 1.0
± 12.2
| 1.6
± 9.4 †
| | 0.1
± 0.2
| 0.2
± 0.3
| 0.5
± 0.4
| 1.3
± 0.9
| 0.5
± 0.6
| 0.0
± 0.4
| 0.2
± 0.5
| 0.3
± 0.6
| 0.4
± 0.5
| 0.0
± 0.3
| -0.4
± 0.4
| 0.7
± 0.6
| 0.3
± 0.5
| 0.4
± 0.3
| 0.4
± 0.4
| 0.1
± 0.7
| 0.1
± 0.5
| paired t-test (t: post - base)
| 0.02
| 0.05
| 0.008
| 0.04
| 0.06
| 0.86
| 0.42
| 0.29
| 0.13
| 0.66
| 0.19
| 0.04
| 0.30
| 0.008
| 0.05
| 0.90
| 0.64
| N pat incr glu
| 164 (51)
| 57 (50)
| 20 (53)
| 6 (75)
| 26 (54)
| 24 (45)
| 5 (71)
| 4 (40)
| 6 (50)
| 34 (47)
| 25 (41) †
| 10 (71)
| 8 (44)
| 33 (67)
| 30 (67)
| 4 (31) †
| 5 (42)
| Power to detect 20mg/dl
| 1.00
| 1.0
| 1.0
| 0.52
| 0.78
| 0.98
| 0.78
| 0.65
| 0.84
| 1.0
| 0.97
| 0.64
| 0.87
| 1.0
| 0.97
| 0.60
| 0.79
|
SE = Sertraline, FL = fluoxetine, PA = paroxetine, AT = atorvastatin, SI = simvastatin, RO = rosuvastatin, LO = lovastatin, PR = pravastatin. † Identifies values which are significantly (p ≤ 0.05) different when compared to the corresponding values under PR and PA Combination therapy.
|
скачати
|